Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis
NCT00511394 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2008-10-15
Summary
Cirrhosis is frequently complicated by derangement of body fluid homeostasis resulting in accumulation of large amounts of extracellular fluid in the peritoneal cavity (ascites) and interstitial tissue (edema). Studies showed that patients with cirrhosis and ascites have marked circulatory dysfunction. Albumin infusions have been used for many years in the management of patients with cirrhosis and ascites in an attempt to reduce the formation of ascites and/or improve circulatory and renal function. While some of these indications for albumin infusions are supported by the results of randomised studies, others are based on clinical experience and have not been proved in prospective investigations. Therefore, the use of albumin infusions in patients with cirrhosis is controversial. Recently, this debate has been fostered by the high cost and limited availability of albumin and the results of a meta-analysis showing that albumin administration may increase mortality in critically ill patients. In cirrhotics, there is a significant improvement in the low effective arterial blood volume, which may be important in the prevention of circulatory dysfunction and in preventing renal impairment. However, in an already fluid overload state such as that of cirrhosis, albumin infusion predisposes the individual to develop pulmonary edema. There is no study demonstrating acute effect of albumin infusion on hemodynamic parameters, in cirrhotic patients. Neither is there is data concerning comparison between albumin and normal saline. It is postulated that it may increase portal pressure thereby increasing the risk of variceal bleed. This study hypothesizes that albumin infusion might lead to alteration in portal and pulmonary hemodynamics in decompensated cirrhotic patients. Included patients of cirrhosis with ascites (based on inclusion and exclusion criteria) will undergo baseline investigations (systemic hemodynamics, pulmonary hemodynamics, portal hemodynamics). They will be randomized into two groups, each of 8. One group will receive infusion of 100 ml 20% albumin over 3 hours, and the other will receive infusion of 100 ml normal saline over 3 hours. Repeat hemodynamic studies will be performed after the infusion finishes. All results will be expressed as mean ± SD or frequency (%). Comparisons will be performed by the Student's t test or with the Wilcoxon's test
Conditions
- Cirrhosis
- Ascites
Interventions
- DRUG
-
20% Human Albumin
Infusion of 100 mL of 20% Albumin over 3 hours
- DRUG
-
Normal Saline
Infusion of 100 mL of Normal Saline
Sponsors & Collaborators
-
Govind Ballabh Pant Hospital
lead OTHER_GOV
Principal Investigators
-
Shiv K Sarin, MD, DM · Govind Ballabh Pant Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-05-31
- Primary Completion
- 2008-12-31
- Completion
- 2008-12-31
Countries
- India
Study Locations
More Related Trials
-
To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.
NCT02467322 ·Status: COMPLETED ·Phase: NA
-
Midodrine and Albumin in Patients With Refractory Ascites
NCT04621617 ·Status: UNKNOWN ·Phase: PHASE3
-
Albumin Infusion in Inpatients With Decompensated Cirrhosis
NCT05719051 ·Status: UNKNOWN
-
Efficacy of Albumin Plus Midodrine v/s Albumin Alone in Reducing Incidence of Paracentesis Induced Circulatory Dysfunctions in ACLF Patients.
NCT04474262 ·Status: UNKNOWN ·Phase: NA
-
Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis.
NCT04679571 ·Status: UNKNOWN ·Phase: NA
-
Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure.
NCT02467348 ·Status: COMPLETED ·Phase: NA
-
Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects
NCT05249374 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Low-dose Albumin and Midodrine Versus Midodrine Alone in Outcome of Recurrent Ascites in Patients With Decompensated Cirrhosis.
NCT06245590 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis.
NCT04816240 ·Status: UNKNOWN ·Phase: NA
-
Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites
NCT06553456 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites
NCT02173288 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites
NCT06091345 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Terlipressin With Albumin Versus Midodrine With Albumin Versus Albumin Alone in Prevention of Paracentesis Induced Circulatory Dysfunction in Cirrhosis
NCT03144713 ·Status: COMPLETED ·Phase: NA
-
Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.
NCT00968695 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
NCT03451292 ·Status: COMPLETED ·Phase: PHASE3
-
Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D).
NCT05937048 ·Status: COMPLETED ·Phase: NA
-
High-volume Versus Standard Volume Plasma Exchange in Patients With Acute Liver Failure With Cerebral Edema
NCT06515145 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
NCT00108355 ·Status: COMPLETED ·Phase: PHASE4
-
Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
NCT05056220 ·Status: RECRUITING ·Phase: PHASE3
-
Body Composition Analysis in Cirrhotic Undergoing Paracentesis
NCT02022150 ·Status: UNKNOWN
-
Comparison of Crystalloid and Colloid I.V Fluid Therapy in Prevention of Paracentesis Induced Circulatory Dysfunction (PICD) and Renal Dysfunction in Patients With Decompensated Liver Cirrhosis in Egypt: a Randomized Piolet Study
NCT05220891 ·Status: UNKNOWN
-
Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis
NCT04109144 ·Status: WITHDRAWN ·Phase: PHASE2
-
Refractory Ascitis Diagnosis by the Study of Labelled Albumin Pharmacokinetics
NCT02818673 ·Status: UNKNOWN ·Phase: PHASE3
-
Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation
NCT00839358 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis
NCT00886925 ·Status: COMPLETED ·Phase: PHASE4